Use of Rabenid for different indications.
Rabenid (sulfinpyrazone) was used in 95 patients suffering from different diseases and treated at the departments could be demonstrated in association with or as a primary cause of the disease. Serum uric acid level was measured as an objective parameter. In response to Rabenid a drastic fall of this value could be observed. The drug influences favourably the serum cholesterol and triglyceride values as well. In patients exposed to the risk of thrombosis, new or recurrent thrombosis did not develop during the observation period and Rabenid was, in general, well tolerated by all patients. Attention has been called to the close correlation between hyperuricaemia, obesity, diabetes, atherosclerosis, hypertensions, and hyperlipaemia and the therapeutic and prophylactic value of the examined drug has been emphasized from this respect.
Nagy
F
F
Schöpf Mérei Agost Hospital, Budapest.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D013442:Sulfinpyrazone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
D014527:Uric Acid; D013442:Sulfinpyrazone